Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Shock. 2017 Jun;47(6):688–695. doi: 10.1097/SHK.0000000000000806

Figure 1. A and B: Interleukin-6 and C-reactive protein levels during the first week of ARDS.

Figure 1

Box plots of log10 IL-6 (pg/ml) and C-reactive protein (mg/l) plasma concentrations on days 0, 3 and 7 in all 51 patients studied. Open boxes - corticosteroids/usual care, gray boxes - placebo/usual care. These data represent a subset of previously described data (19, 24). A: Plasma IL-6 levels during first week of ARDS. No significant change was found in IL-6 by day 3 in the placebo/usual care group compared to day 0 (b p=NS). In contrast, in the corticosteroid/usual care group, levels were significantly lower at ARDS day 3 compared to day 0 (a p<0.001). In both groups at day 7, levels were significantly lower than day 0 levels (c p<0.001 for corticosteroid/usual care group, d p=0.0001 for placebo/usual care group). B: Plasma C-reactive protein levels during first week of ARDS. No significant change was found in C-reactive protein by day 3 in the placebo/usual care group compared to day 0 (b p=NS). In contrast, in the corticosteroid/usual care group, levels were significantly lower at ARDS day 3 compared to day 0 (a p<0.001). In both groups at day 7, levels were significantly lower than day 0 levels (c p<0.001 for corticosteroid/usual care group, d p=0.004 for placebo/usual care group,).